抗纤维化药尼达尼布治疗类风湿关节炎相关间质性肺病的真实世界证据:74例全国多中心研究
西班牙全国多中心研究纳入74例因进行性纤维化性间质性肺病加用尼达尼布治疗的类风湿关节炎相关间质性肺病患者,评估有效性、药物留存率与安全性,主要终点为用力肺活量变化;中位随访15个月未见平均FVC或DLCO显著下降,尼达尼布留存率78.4%,胃肠道不良事件是最常见停药原因。
要点
- 中位随访15个月未见平均FVC或DLCO显著下降,尼达尼布留存率78.4%
- 随访期间16.7%的患者出现间质性肺病进展或进行性肺纤维化
- 与INBUILD试验相比,真实世界患者年龄更大、吸烟暴露更高、ILD病程更长、联合免疫抑制治疗更频繁
核心结论
- 尼达尼布似乎对进行性纤维化性类风湿关节炎相关间质性肺病有效且相对安全,尽管与INBUILD试验存在临床差异。
研究设计与样本
- 西班牙全国多中心研究,纳入74例因进行性纤维化性间质性肺病加用尼达尼布的类风湿关节炎相关间质性肺病患者(31例女性/43例男性),平均年龄69.3±8.8岁。
- 主要终点为用力肺活量(FVC)变化,并与INBUILD试验中的类风湿关节炎相关间质性肺病患者(n=89,其中42例接受尼达尼布)进行比较研究。
主要发现
- 从间质性肺病诊断至开始抗纤维化治疗的中位病程为51[22-77.5]个月。
- 除糖皮质激素(n=54)外,尼达尼布联合cDMARD(n=21)、bDMARD(n=46)和/或JAKi(n=4),单药治疗n=3。
- 开始尼达尼布前一年平均FVC为81.9±21.2(%预计值),基线平均FVC为73.7±22.5(%预计值)。
- 中位随访15[10-22,4-9]个月后,未观察到平均FVC或DLCO值显著下降;DLCO和FVC的演变与假设不用药时变化的预测模型显著不同。
- 尼达尼布留存率为78.4%;随访期间16.7%的患者出现间质性肺病进展或进行性肺纤维化;胃肠道不良事件是尼达尼布停药最常见原因。
关键数值与推荐
- 与INBUILD试验相比,真实世界患者年龄更大、烟草暴露更高、间质性肺病诊断后时间更长、联合免疫抑制治疗更频繁,但两组基线平均FVC和DLCO值相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effectiveness and safety of the antifibrotic drug nintedanib in rheumatoid arthritis (RA)-related interstitial lung disease (ILD) and a progressive phenotype in clinical practice. METHODS: National Spanish multicenter study of RA-ILD patients to whom nintedanib was added due to progressive fibrosing ILD. Outcome variables were effectiveness, retention rate and safety. Forced vital capacity (FVC) evolution was the primary endpoint. A comparative study between our cohort and those RA-ILD patients included in the INBUILD trial (n = 89, 42 treated with nintedanib) was performed. RESULTS: A total of 74 patients (31 women/43 men) were collected, mean age of 69.3 ± 8.8 years. Median [IQR] ILD duration up to antifibrotic initiation was 51 [22-77.5] months. Besides corticosteroids (n = 54), nintedanib was used combined with cDMARD (n = 21), bDMARD (n = 46) and/or JAKi (n = 4) and monotherapy (n = 3). Mean FVC one year before nintedanib start was 81.9 ± 21.2 (% pred.), whilst mean baseline FVC was 73.7 ± 22.5 (% pred.). After a median follow-up of 15 [10-22, 4-9] months, no significant decline in mean FVC or DLCO values was observed. Moreover, the evolution of DLCO and FVC significantly differed from a predictive model that assumed their changes without the drug. The retention rate with nintedanib was 78.4 %. During the follow up, 16.7 % of patients showed ILD progression or progressive pulmonary fibrosis. Gastrointestinal adverse events were the most common reason for nintedanib discontinuation. Compared with INBUILD trial, patients from clinical practice were older, had a higher tobacco exposure, time since ILD diagnosis was longer and treatment with combined immunosuppressants was more frequent. However, baseline mean values of FVC and DLCO were similar in both groups. CONCLUSION: Nintedanib seems to be effective and relatively safe in progressive fibrosing RA-ILD despite clinical differences with the INBUILD trial.
引用
- Atienza-Mateo B, Serrano-Combarro A, Loarce Martos J, et al. Real-world evidence of the antifibrotic nintedanib in rheumatoid arthritis-interstitial lung disease. National multicenter study of 74 patients. Semin Arthritis Rheum. 2025. PMID: 40117729. doi:10.1016/j.semarthrit.2025.152710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。